Overview
NICE is unable to make a recommendation on lisocabtagene maraleucel (Breyanzi) for treating relapsed or refractory follicular lymphoma in adults after 2 or more lines of systemic treatment. This is because the company did not provide an evidence submission.
Last reviewed: 20 August 2026
Next review: We will review this decision if the company decides to make a submission.